KEYS vs SKYE · P/E 57, rev $4.98B vs $25.0M cap
Keysight Technologies Inc (KEYS) versus Skye Bioscience, Inc. Common Stock (SKYE) — a side-by-side from cached financials, not a winner call.
Keysight Technologies Inc (KEYS) is a scientific & technical instruments company listed on US.
Skye Bioscience, Inc. Common Stock (SKYE) is a biotechnology company listed on NASDAQ.
Latest reported KEYS revenue for 2024-10-31 was $4.98B. Net income was $614.0M. Revenue was down 8.9% from 2023-10-31 to 2024-10-31. KEYS currently screens at market cap $59.84B and trailing P/E 56.5.
SKYE does not have a complete income-statement cache yet.
KEYS currently screens at market cap $59.84B and trailing P/E 56.5. SKYE currently screens at market cap $25.0M.
Not investment advice. Open the KEYS and SKYE stock pages for the full models.
Not investment advice.